Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury

Stoyanoff, Tania Romina; Rodríguez, José Carlos; Todaro, Juan Santiago; Colavita, Juan Pablo Melana; Torres, Adriana M.; Aguirre, María Victoria

doi:10.1016/j.biopha.2018.08.087

Cited by 43 publications

(35 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Renoprotective effects of EPO in mice with septic acute kidney injury has been observed and has been linked to attenuation of microvascular damage, reducing renal inflammatory response and improvement of renal tissue oxygenation through the decrease of hypoxia‐inducible factor‐1 alpha, inducible nitric oxide synthase, and NF‐κB and also enhancement of erythropoietin receptor (EPO‐R), PeCAM‐1, vascular endothelial growth factor, and VEGFR‐2 expression 8 …”

Section: Discussionmentioning

confidence: 99%

Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects?

Hadadi

Mortezazadeh

Kolahdouzan

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

An 80-year-old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever, and critically low O 2 saturation and definitive chest computerized tomography scan findings in favor of COVID-19 and positive PCR results in 48 hours. He received antiviral treatment plus recombinant human erythropoietin (rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the severe acute respiratory syndrome coronavirus 2 virus through multiple mechanisms including cytokine modulation, antiapoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus.

show abstract

Section: Discussionmentioning

confidence: 99%

Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects?

Hadadi

Mortezazadeh

Kolahdouzan

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…EPO has shown protective effects in several experimental AKI models, through various mechanisms including the regulation of microvascular injury [7], the reduction in tubulointerstitial injury (independent of its hemopoietic effects) [16], anti-inflammatory and anti-apoptotic effects [17], decreased fibrocyte accumulation [18], and the modulation of macrophage polarization [19,20]. Notably, EPO has shown efficacy in animal models of IR-AKI [21], as well as in an in vitro hypoxia-reoxygenation study [22], via the regulation of PI3K/Akt signaling.…”

Section: Discussionmentioning

confidence: 99%

“…Treatment with erythropoiesis-stimulating agents has led to significant improvements in patients' quality of life [5,6]. Furthermore, the anti-inflammatory and antioxidant effects of EPO in AKI have been demonstrated in renal cell and animal models [7]. Here, we investigated the renoprotective mechanisms of EPO in IR-AKI mice, as well as the role of the inflammasome in mediating these effects.…”

Section: Introductionmentioning

confidence: 99%

Erythropoietin Ameliorates Ischemia/Reperfusion-Induced Acute Kidney Injury via Inflammasome Suppression in Mice

Kwak

Kim

Jang

et al. 2020

IJMS

View full text Add to dashboard Cite

Acute kidney injury (AKI) is the most common condition in hospitalized patients. As ischemia/reperfusion-induced AKI (IR-AKI) is as a major contributor to end-stage disease, an effective therapeutic intervention for IR-AKI is imperative. Erythropoietin (EPO) is a potent stimulator of erythroid progenitor cells and is significantly upregulated during hypoxia. Here, we investigated the renoprotective effects of EPO in an IR-AKI mouse model. Mice were assigned to sham, EPO only, and IR only groups, and the IR group was treated with EPO prior to injury. EPO was administered twice at 30 min prior to bilateral renal artery occlusion, and 5 min before reperfusion, with all mice sacrificed 24 h after IR-AKI. The serum was harvested for renal functional measurements. The kidneys were subjected to histological evaluation, and the biochemical changes associated with renal injury were assessed. EPO significantly attenuated the renal dysfunction associated with IR-AKI, as well as tissue injury. Apoptotic cell death and oxidative stress were significantly reduced in EPO-treated mice. Macrophage infiltration and expression of ICAM-1 and MCP-1 were also significantly reduced in EPO-treated mice. Furthermore, the expression of inflammasome-related factors (NLRP1, NLRP3, and caspase-1 cleavage), via the activation of the COX-2 and NF-κB signaling pathways were significantly reduced following EPO treatment. To our knowledge, this is the first study to demonstrate that inflammasome-mediated inflammation might be a potential target of EPO as a treatment for ischemic AKI.

show abstract

“…Menos receptores ECA2 explicarían la disminución de la COVID-19 en poblaciones de altura, así como el decremento de mortalidad, pues al haber menos receptores ECA2 la carga viral que reciben los afectados será menor y de ella depende su evolución 9 . La hipoxia hipobárica incrementa la eritropoyetina (EPO), hormona citoprotectora multifuncional, que disminuye la inflamación por shock séptico y mejora la lesión microvascular endotoxémica 10 , lo que también podría explicar por qué los pacientes COVID-19 fallecen menos en la altura. En Francia se halló que los malos resultados clínicos y virológicos en pacientes COVID-19 tratados con hidroxicloroquina-azitromicina se asociaron al uso de bloqueadores de AT1 11 .…”

unclassified

En la altura la COVID-19 es menos frecuente: la experiencia del Perú

Accinelli

León-Abarca

2020

Archivos de Bronconeumología

View full text Add to dashboard Cite

Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury

Cited by 43 publications

References 45 publications

Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects?

Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects?

Erythropoietin Ameliorates Ischemia/Reperfusion-Induced Acute Kidney Injury via Inflammasome Suppression in Mice

En la altura la COVID-19 es menos frecuente: la experiencia del Perú

Contact Info

Product

Resources

About